Based on these data, nivolumab was approved for adjuvant treatment of ESCC and EAC of the esophagus after neoadjuvant radiochemotherapy and R0 resection with incomplete response without limitations by PD-L1 positivity, despite the rather low efficacy in the CPS < 5 subgroup (Figure 1). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.